MARIETTA, Ga., Sept. 05, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that senior management will participate in the following investor conferences:
H.C. Wainwright 25th Annual Global Investment Conference
Presentation: Tuesday, September 12, 2023 at 12:30 PM ET
Webcast: Click here to access
Northland Capital Markets Institutional Investor Conference (Virtual)
Participation: Tuesday, September 19, 2023
Cantor Fitzgerald Global Healthcare Conference 2023
Presentation: Wednesday, September 27, 2023 at 10:55 AM ET
Webcast: Click here to access
Institutional investors interested in meeting with senior management may contact their respective H.C. Wainwright, Northland Capital, or Cantor Fitzgerald representative.
A live webcast of each presentation will be available on the Events page of the Investors section of the Company’s website at www.mimedx.com or through the conference site by using the links above. A replay will be available on the Company’s website following the event.
About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.
Contact:
Matt Notarianni
Investor Relations
470-304-7291
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$6.49 |
| Daily Change: | 0.15 2.37 |
| Daily Volume: | 311,348 |
| Market Cap: | US$953.710M |
May 05, 2025 April 10, 2025 February 27, 2025 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
